Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.

The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted agent (ARTA).

The objective was to compare characteristics and treatment patterns of patients from a real-world dataset with the CARD population.

Real-world data were collected from Medimix Live TrackerTM, a retrospective, global oncology database of healthcare professional-reported electronic patient medical forms (2001-2019), with data from patients from Europe, USA, Brazil and Japan. The database contained patient, tumor and treatment information for 12,140 patients who received ≥1 line of treatment for mCRPC. A CARD-like cohort included patients treated with docetaxel, prior abiraterone/enzalutamide and cabazitaxel.

A large proportion of patients received ≥2 lines of ARTA (35.1%) with 42% of patients who received a first-line ARTA receiving another ARTA in second line. Of the total patients, 452 were eligible for the CARD-like cohort. Median age of the CARD-like cohort was comparable to CARD (73 vs 70 years). The CARD-like cohort had unfavorable disease characteristics vs CARD: ECOG PS ≥ 2 (45% vs 4.7%); metastasis at diagnosis (46% vs 38%) and Gleason 8-10 (65% vs 57%). More patients in the CARD-like cohort received ARTA before docetaxel (48% vs 39%) and received the first ARTA for >12 months (30% vs 17%) compared with CARD. Despite more patients in the CARD-like cohort receiving the lower 20 mg/m2 dose of cabazitaxel (55% vs 21%), cabazitaxel treatment duration was similar (21.9 vs 22.0 weeks).

Sequential use of ARTA was frequent. Results indicate the CARD population is reflective of routine clinical practice and duration of response to cabazitaxel was similar in a real-world population.

Prostate cancer and prostatic diseases. 2022 Jan 17 [Epub ahead of print]

Ronald de Wit, Stephen J Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K Morgans

Erasmus Medical Center, Rotterdam, The Netherlands. ., Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., George Pompidou European Hospital, University of Paris, Paris, France., PPD, Sofia, Bulgaria., Medimix, Miami, FL, USA., University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sanofi, Global Medical Oncology, Cambridge, MA, USA., Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Go Beyond the Abstract and Read a Commentary by the Authors